Abstract
In the News Focus story “The human genome (patent) project” (4 February, p. [530][1]), S. Kean focuses on the concern that large numbers of human gene patents and assignees holding these patents can block or have a chilling effect on commercialization. We believe that Kean may have overstated
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have